It's Uncomplicated: Prevention of Urinary Tract Infections in an Era of Increasing Antibiotic Resistance

Overview

Journal PLoS Pathog

Specialty Microbiology

Date 2024 Feb 1

PMID 38300901

Authors

Lori L Burrows

Affiliations

Soon will be listed here.

Citing Articles

Disparities in the Prevalence of Urinary Diseases Among Prisoners in Taiwan: Population-Based Cross-Sectional Study.

Wang Y, Jiesisibieke Z, Yang Y, Wang B, Hsiung M, Tung T JMIR Public Health Surveill. 2024; 10:e60136.

PMID: 39727265 PMC: 11693784. DOI: 10.2196/60136.

The challenge of antimicrobial resistance (AMR): current status and future prospects.

Ferrara F, Castagna T, Pantolini B, Campanardi M, Roperti M, Grotto A Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(12):9603-9615.

PMID: 39052061 DOI: 10.1007/s00210-024-03318-x.

References

Flores-Mireles A, Walker J, Caparon M, Hultgren S . Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015; 13(5):269-84. PMC: 4457377. DOI: 10.1038/nrmicro3432. View

. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022; 399(10325):629-655. PMC: 8841637. DOI: 10.1016/S0140-6736(21)02724-0. View

Foxman B . Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am. 2014; 28(1):1-13. DOI: 10.1016/j.idc.2013.09.003. View

Hrbacek J, cermak P, Zachoval R . Current Antibiotic Resistance Trends of Uropathogens in Central Europe: Survey from a Tertiary Hospital Urology Department 2011-2019. Antibiotics (Basel). 2020; 9(9). PMC: 7559630. DOI: 10.3390/antibiotics9090630. View

Almant M, Moreau V, Kovensky J, Bouckaert J, Gouin S . Clustering of Escherichia coli type-1 fimbrial adhesins by using multimeric heptyl α-D-mannoside probes with a carbohydrate core. Chemistry. 2011; 17(36):10029-38. DOI: 10.1002/chem.201100515. View

van Driel A, Notermans D, Meima A, Mulder M, Donker G, Stobberingh E . Antibiotic resistance of Escherichia coli isolated from uncomplicated UTI in general practice patients over a 10-year period. Eur J Clin Microbiol Infect Dis. 2019; 38(11):2151-2158. PMC: 6800841. DOI: 10.1007/s10096-019-03655-3. View

Al-Anany A, Hooey P, Cook J, Burrows L, Martyniuk J, Hynes A . Phage Therapy in the Management of Urinary Tract Infections: A Comprehensive Systematic Review. Phage (New Rochelle). 2023; 4(3):112-127. PMC: 10523411. DOI: 10.1089/phage.2023.0024. View

Taha R, Kader O, Shawky S, Rezk S . Ceftazidime-Avibactam plus aztreonam synergistic combination tested against carbapenem-resistant Enterobacterales characterized phenotypically and genotypically: a glimmer of hope. Ann Clin Microbiol Antimicrob. 2023; 22(1):21. PMC: 10029209. DOI: 10.1186/s12941-023-00573-3. View

Aslam S, Albo M, Brubaker L . Recurrent Urinary Tract Infections in Adult Women. JAMA. 2020; 323(7):658-659. DOI: 10.1001/jama.2019.21377. View

10.

Stamm W, Raz R . Factors contributing to susceptibility of postmenopausal women to recurrent urinary tract infections. Clin Infect Dis. 2000; 28(4):723-5. DOI: 10.1086/515209. View

11.

Afshar K, Fleischmann N, Schmiemann G, Bleidorn J, Hummers-Pradier E, Friede T . Reducing antibiotic use for uncomplicated urinary tract infection in general practice by treatment with uva-ursi (REGATTA) - a double-blind, randomized, controlled comparative effectiveness trial. BMC Complement Altern Med. 2018; 18(1):203. PMC: 6029138. DOI: 10.1186/s12906-018-2266-x. View

12.

Medina M, Castillo-Pino E . An introduction to the epidemiology and burden of urinary tract infections. Ther Adv Urol. 2019; 11:1756287219832172. PMC: 6502976. DOI: 10.1177/1756287219832172. View

13.

Langford B, Soucy J, Leung V, So M, Kwan A, Portnoff J . Antibiotic resistance associated with the COVID-19 pandemic: a systematic review and meta-analysis. Clin Microbiol Infect. 2022; 29(3):302-309. PMC: 9733301. DOI: 10.1016/j.cmi.2022.12.006. View

14.

Toosky M, Grunwald J, Pala D, Shen B, Zhao W, DAgostini C . A rapid, point-of-care antibiotic susceptibility test for urinary tract infections. J Med Microbiol. 2019; 69(1):52-62. PMC: 7440674. DOI: 10.1099/jmm.0.001119. View

15.

Kranjcec B, Papes D, Altarac S . D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J Urol. 2013; 32(1):79-84. DOI: 10.1007/s00345-013-1091-6. View

16.

Hatton N, Baumann C, Fascione M . Developments in Mannose-Based Treatments for Uropathogenic Escherichia coli-Induced Urinary Tract Infections. Chembiochem. 2020; 22(4):613-629. PMC: 7894189. DOI: 10.1002/cbic.202000406. View

17.

Foxman B . Editorial commentary: extended-spectrum β-lactamase-producing escherichia coli in the united states: time to rethink empirical treatment for suspected E. coli infections?. Clin Infect Dis. 2012; 56(5):649-51. DOI: 10.1093/cid/cis947. View

18.

Gharbi M, Drysdale J, Lishman H, Goudie R, Molokhia M, Johnson A . Antibiotic management of urinary tract infection in elderly patients in primary care and its association with bloodstream infections and all cause mortality: population based cohort study. BMJ. 2019; 364:l525. PMC: 6391656. DOI: 10.1136/bmj.l525. View

19.

Gouin S, Wellens A, Bouckaert J, Kovensky J . Synthetic multimeric heptyl mannosides as potent antiadhesives of uropathogenic Escherichia coli. ChemMedChem. 2009; 4(5):749-55. DOI: 10.1002/cmdc.200900034. View

20.

Terlizzi M, Gribaudo G, Maffei M . UroPathogenic (UPEC) Infections: Virulence Factors, Bladder Responses, Antibiotic, and Non-antibiotic Antimicrobial Strategies. Front Microbiol. 2017; 8:1566. PMC: 5559502. DOI: 10.3389/fmicb.2017.01566. View